Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
NCT ID: NCT04842305
Last Updated: 2021-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2021-04-30
2024-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of COVID-19 in Saliva Collection
NCT04386551
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers
NCT04525417
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
NCT04664023
SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19
NCT04979871
IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
NCT04402814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
G1: Control group
SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
G2: COVID-19 infected
Persons who have had COVID-19
Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
G3: COVID-19 vaccinated
Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
G4: COVID-19 infected and vaccinated
Individuals who have been infected with COVID-19 and subsequently been vaccinated
Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood- and saliva tests
Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both Hospital staff as well as non-health care workers will be invited to participate
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lenanrt Friis-Hansen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lenanrt Friis-Hansen
Department of Clinical Biochemistry MD, DMSc, Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P-2021-224
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.